context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The U.S. GAAP purchase price allocated to the transaction was $ 695 million, which consisted of $ 350 million of cash consideration paid and estimated contingent consideration at the date of acquisition valued at approximately $ 345 million. The fair value of the contingent consideration was valued using a Monte Carlo ... | text | 345 | monetaryItemType | text: <entity> 345 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. GAAP purchase price allocated to the transaction was $ 695 million, which consisted of $ 350 million of cash consideration paid and estimated contingent consideration at the date of acquisition valued at approximately $ 345 mi... | us-gaap:BusinessCombinationContingentConsiderationLiability |
On February 25, 2025, in order to preserve the ongoing continuity of the development programs for selatogrel and cenerimod considering certain capital structuring steps announced by Idorsia to secure its ongoing operations, Viatris and Idorsia entered into a letter agreement to amend certain terms of the original agree... | text | 100 | monetaryItemType | text: <entity> 100 </entity> <entity type> monetaryItemType </entity type> <context> On February 25, 2025, in order to preserve the ongoing continuity of the development programs for selatogrel and cenerimod considering certain capital structuring steps announced by Idorsia to secure its ongoing operations, Viatris and... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther |
The goodwill of $ 19.5 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products, including additional indications, to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in ... | text | 19.5 | monetaryItemType | text: <entity> 19.5 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 19.5 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products, including additional indications, to be developed in the future. All of the goodw... | us-gaap:Goodwill |
During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for vested share-based awards, and the repayment of the Oyster Point debt. | text | 427.4 | monetaryItemType | text: <entity> 427.4 </entity> <entity type> monetaryItemType </entity type> <context> During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for ve... | us-gaap:BusinessCombinationConsiderationTransferred1 |
During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for vested share-based awards, and the repayment of the Oyster Point debt. | text | 11 | perShareItemType | text: <entity> 11 </entity> <entity type> perShareItemType </entity type> <context> During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for veste... | us-gaap:BusinessAcquisitionSharePrice |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. During the year... | text | 22.8 | monetaryItemType | text: <entity> 22.8 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recor... | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
During the year ended December 31, 2023, adjustments were made to the preliminary purchase price recorded at January 3, 2023, and are reflected as “Measurement Period Adjustments” in the table below. The U.S. GAAP purchase price was $ 392.7 million, net of cash acquired. The allocation of the purchase price to the asse... | text | 392.7 | monetaryItemType | text: <entity> 392.7 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, adjustments were made to the preliminary purchase price recorded at January 3, 2023, and are reflected as “Measurement Period Adjustments” in the table below. The U.S. GAAP purchase price was ... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
The Company recorded a step-up in the fair value of inventory of approximately $ 29.3 million, which was fully amortized during the year ended December 31, 2023 and was included in | text | 29.3 | monetaryItemType | text: <entity> 29.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company recorded a step-up in the fair value of inventory of approximately $ 29.3 million, which was fully amortized during the year ended December 31, 2023 and was included in </context> | us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory |
The identified intangible assets of $ 334.0 million are comprised of product rights and licenses related to a commercial asset, Tyrvaya®, for the treatment of dry eye disease, that have an estimated useful life of 10 years. Significant assumptions utilized in the valuation of identified intangible assets were based on ... | text | 334.0 | monetaryItemType | text: <entity> 334.0 </entity> <entity type> monetaryItemType </entity type> <context> The identified intangible assets of $ 334.0 million are comprised of product rights and licenses related to a commercial asset, Tyrvaya®, for the treatment of dry eye disease, that have an estimated useful life of 10 years. Significa... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles |
The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be d... | text | 6.7 | monetaryItemType | text: <entity> 6.7 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Mar... | us-gaap:Goodwill |
The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be d... | text | 41.7 | monetaryItemType | text: <entity> 41.7 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Ma... | us-gaap:Revenues |
The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be d... | text | 163.1 | monetaryItemType | text: <entity> 163.1 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed M... | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a... | text | 281 | monetaryItemType | text: <entity> 281 </entity> <entity type> monetaryItemType </entity type> <context> On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under devel... | us-gaap:BusinessCombinationConsiderationTransferred1 |
On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a... | text | 13.5 | percentItemType | text: <entity> 13.5 </entity> <entity type> percentItemType </entity type> <context> On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under devel... | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a... | text | 25.0 | monetaryItemType | text: <entity> 25.0 </entity> <entity type> monetaryItemType </entity type> <context> On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under deve... | us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent |
The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5 % equity interest in Famy Life Sciences to fair value, which was recogni... | text | 18.9 | monetaryItemType | text: <entity> 18.9 </entity> <entity type> monetaryItemType </entity type> <context> The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-... | us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee |
The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5 % equity interest in Famy Life Sciences to fair value, which was recogni... | text | 13.5 | percentItemType | text: <entity> 13.5 </entity> <entity type> percentItemType </entity type> <context> The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-e... | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP p... | text | 325.0 | monetaryItemType | text: <entity> 325.0 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were reco... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP p... | text | 281 | monetaryItemType | text: <entity> 281 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were record... | us-gaap:BusinessCombinationConsiderationTransferred1 |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP p... | text | 43.9 | monetaryItemType | text: <entity> 43.9 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recor... | us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP p... | text | 13.5 | percentItemType | text: <entity> 13.5 </entity> <entity type> percentItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were record... | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alternative future use. The fair value of IPR&D of $ 290.0 million was based on the excess... | text | 290.0 | monetaryItemType | text: <entity> 290.0 </entity> <entity type> monetaryItemType </entity type> <context> The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alt... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles |
The goodwill of $ 89.2 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be ... | text | 89.2 | monetaryItemType | text: <entity> 89.2 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 89.2 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed M... | us-gaap:Goodwill |
During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of | text | 69.9 | monetaryItemType | text: <entity> 69.9 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a com... | us-gaap:OtherNonoperatingIncomeExpense |
During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of | text | 168.0 | monetaryItemType | text: <entity> 168.0 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a co... | us-gaap:OtherNonoperatingIncomeExpense |
During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of | text | 17.7 | monetaryItemType | text: <entity> 17.7 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a com... | us-gaap:OtherNonoperatingIncomeExpense |
In the third quarter of 2023, Viatris executed an agreement to divest its women’s healthcare business to Insud Pharma, S.L., a leading Spanish multinational pharmaceutical company. The divestiture of the women’s healthcare business was primarily related to our oral and injectable contraceptives and did not include all ... | text | 77.8 | monetaryItemType | text: <entity> 77.8 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, Viatris executed an agreement to divest its women’s healthcare business to Insud Pharma, S.L., a leading Spanish multinational pharmaceutical company. The divestiture of the women’s healthcare business wa... | us-gaap:GainLossOnSaleOfBusiness |
In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K.... | text | 156.2 | monetaryItemType | text: <entity> 156.2 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty phar... | us-gaap:GainLossOnSaleOfBusiness |
In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K.... | text | 10.8 | monetaryItemType | text: <entity> 10.8 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharm... | us-gaap:GainLossOnSaleOfBusiness |
The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a tot... | text | 734.7 | monetaryItemType | text: <entity> 734.7 </entity> <entity type> monetaryItemType </entity type> <context> The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. ... | us-gaap:AssetImpairmentCharges |
The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a tot... | text | 580.1 | monetaryItemType | text: <entity> 580.1 </entity> <entity type> monetaryItemType </entity type> <context> The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. ... | us-gaap:GoodwillImpairmentLoss |
expense), and a charge of approximately $ 154.7 million to write down the disposal group to fair value, less cost to sell (recorded as a component of | text | 154.7 | monetaryItemType | text: <entity> 154.7 </entity> <entity type> monetaryItemType </entity type> <context> expense), and a charge of approximately $ 154.7 million to write down the disposal group to fair value, less cost to sell (recorded as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown |
in the consolidated statement of operations. During the year ended December 31, 2024, the Company recorded additional pre-tax charges of approximately $ 369.0 million to further write down the disposal group to fair value, less cost to sell. The additional charges were recorded as a component of | text | 369.0 | monetaryItemType | text: <entity> 369.0 </entity> <entity type> monetaryItemType </entity type> <context> in the consolidated statement of operations. During the year ended December 31, 2024, the Company recorded additional pre-tax charges of approximately $ 369.0 million to further write down the disposal group to fair value, less cost ... | us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown |
On October 1, 2023, Viatris executed an agreement to divest its API business in India to Matrix Pharma Private Limited, a privately held pharmaceutical company based in India. The transaction included three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-party API sales. Via... | text | 47.8 | monetaryItemType | text: <entity> 47.8 </entity> <entity type> monetaryItemType </entity type> <context> On October 1, 2023, Viatris executed an agreement to divest its API business in India to Matrix Pharma Private Limited, a privately held pharmaceutical company based in India. The transaction included three manufacturing sites and a R... | us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million... | text | 374.2 | monetaryItemType | text: <entity> 374.2 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 ... | us-gaap:AssetImpairmentCharges |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million... | text | 117.0 | monetaryItemType | text: <entity> 117.0 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 ... | us-gaap:GoodwillImpairmentLoss |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million... | text | 84.3 | monetaryItemType | text: <entity> 84.3 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 m... | us-gaap:AssetImpairmentCharges |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million... | text | 172.9 | monetaryItemType | text: <entity> 172.9 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 ... | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million... | text | 136.4 | monetaryItemType | text: <entity> 136.4 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 ... | us-gaap:AssetImpairmentCharges |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million... | text | 85.2 | monetaryItemType | text: <entity> 85.2 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 m... | us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billio... | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash p... | us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billio... | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash p... | us-gaap:ProceedsFromDivestitureOfBusinesses |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billio... | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash p... | us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billio... | text | 373.5 | monetaryItemType | text: <entity> 373.5 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion ca... | us-gaap:EquitySecuritiesFvNiGainLoss |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billio... | text | 21.1 | monetaryItemType | text: <entity> 21.1 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cas... | us-gaap:EquitySecuritiesFvNiGainLoss |
The Biocon Agreement provided for a closing working capital target of $ 250 million, of which $ 220 million was paid by Viatris to Biocon Biologics during 2023. In addition, pursuant to the terms of the Biocon Agreement, the Company was entitled to receive a total of $ 335 million of additional cash payments in 2024 as... | text | 60.0 | monetaryItemType | text: <entity> 60.0 </entity> <entity type> monetaryItemType </entity type> <context> The Biocon Agreement provided for a closing working capital target of $ 250 million, of which $ 220 million was paid by Viatris to Biocon Biologics during 2023. In addition, pursuant to the terms of the Biocon Agreement, the Company w... | us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
Upon closing of the Biocon Biologics Transaction, the Company recognized a gain on sale of approximately $ 1.75 billion for the difference between the consideration received, including the fair value of the CCPS, and the carrying value of the biosimilars portfolio (including an allocation of goodwill). The gain was rec... | text | 1.75 | monetaryItemType | text: <entity> 1.75 </entity> <entity type> monetaryItemType </entity type> <context> Upon closing of the Biocon Biologics Transaction, the Company recognized a gain on sale of approximately $ 1.75 billion for the difference between the consideration received, including the fair value of the CCPS, and the carrying valu... | us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ 226.9 million and $ 326.1 million for the years ended December 31, 2024, 2023 and 2022,... | text | 454.5 | monetaryItemType | text: <entity> 454.5 </entity> <entity type> monetaryItemType </entity type> <context> Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ ... | us-gaap:InventoryValuationReserves |
Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ 226.9 million and $ 326.1 million for the years ended December 31, 2024, 2023 and 2022,... | text | 479.3 | monetaryItemType | text: <entity> 479.3 </entity> <entity type> monetaryItemType </entity type> <context> Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ ... | us-gaap:InventoryValuationReserves |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expens... | text | 157.7 | monetaryItemType | text: <entity> 157.7 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estim... | us-gaap:CapitalizedComputerSoftwareNet |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expens... | text | 167.2 | monetaryItemType | text: <entity> 167.2 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estim... | us-gaap:CapitalizedComputerSoftwareNet |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expens... | text | 357.0 | monetaryItemType | text: <entity> 357.0 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estim... | us-gaap:Depreciation |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expens... | text | 362.1 | monetaryItemType | text: <entity> 362.1 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estim... | us-gaap:Depreciation |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expens... | text | 349.5 | monetaryItemType | text: <entity> 349.5 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estim... | us-gaap:Depreciation |
The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the... | text | 41.9 | monetaryItemType | text: <entity> 41.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s re... | us-gaap:SupplierFinanceProgramObligation |
The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the... | text | 65.1 | monetaryItemType | text: <entity> 65.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s re... | us-gaap:SupplierFinanceProgramObligation |
Balance as of December 31, 2024 includes a total of $ 378.0 million related to the Idorsia Transaction. Refer to Note 9 | text | 378.0 | monetaryItemType | text: <entity> 378.0 </entity> <entity type> monetaryItemType </entity type> <context> Balance as of December 31, 2024 includes a total of $ 378.0 million related to the Idorsia Transaction. Refer to Note 9 </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance ... | text | 253.1 | monetaryItemType | text: <entity> 253.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in... | us-gaap:OperatingLeaseRightOfUseAsset |
As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance ... | text | 266.4 | monetaryItemType | text: <entity> 266.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in... | us-gaap:OperatingLeaseLiability |
As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 mil... | text | 89.8 | monetaryItemType | text: <entity> 89.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had ... | us-gaap:PaymentsForRent |
As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 mil... | text | 87.6 | monetaryItemType | text: <entity> 87.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had ... | us-gaap:PaymentsForRent |
As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 mil... | text | 90.9 | monetaryItemType | text: <entity> 90.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had ... | us-gaap:PaymentsForRent |
Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 929.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 385.0 million. | text | 385.0 | monetaryItemType | text: <entity> 385.0 </entity> <entity type> monetaryItemType </entity type> <context> Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 929.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 385.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. | text | 351.0 | monetaryItemType | text: <entity> 351.0 </entity> <entity type> monetaryItemType </entity type> <context> Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. | text | 30.0 | monetaryItemType | text: <entity> 30.0 </entity> <entity type> monetaryItemType </entity type> <context> Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 124.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 117.0 million. | text | 117.0 | monetaryItemType | text: <entity> 117.0 </entity> <entity type> monetaryItemType </entity type> <context> Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 124.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 117.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
In conjunction with its annual goodwill impairment test, the Company recorded a goodwill impairment charge of $ 321.0 million during the second quarter of 2024 related to its JANZ reporting unit, which was recorded within | text | 321.0 | monetaryItemType | text: <entity> 321.0 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with its annual goodwill impairment test, the Company recorded a goodwill impairment charge of $ 321.0 million during the second quarter of 2024 related to its JANZ reporting unit, which was recorded within </context> | us-gaap:GoodwillImpairmentLoss |
For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe reporting unit at April 1, 2024, the Company forecasted cash flows for the next 10 years.... | text | 882 | monetaryItemType | text: <entity> 882 </entity> <entity type> monetaryItemType </entity type> <context> For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe repo... | us-gaap:ReportingUnitAmountOfFairValueInExcessOfCarryingAmount |
For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe reporting unit at April 1, 2024, the Company forecasted cash flows for the next 10 years.... | text | 7.9 | percentItemType | text: <entity> 7.9 </entity> <entity type> percentItemType </entity type> <context> For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe repor... | us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount |
In the third quarter of 2023, the Company allocated goodwill of $ 69 million to its women’s healthcare business using a relative fair value approach and reclassified the amount to | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, the Company allocated goodwill of $ 69 million to its women’s healthcare business using a relative fair value approach and reclassified the amount to </context> | us-gaap:GoodwillTransfers |
In the fourth quarter of 2023, the Company allocated goodwill of $ 120 million to its API business in India using a relative fair value approach and reclassified the amount to | text | 120 | monetaryItemType | text: <entity> 120 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2023, the Company allocated goodwill of $ 120 million to its API business in India using a relative fair value approach and reclassified the amount to </context> | us-gaap:GoodwillTransfers |
In the fourth quarter of 2023, the OTC Business met the criteria to be classified as held for sale. The Company allocated goodwill to its OTC Business using a relative fair value approach and recorded a goodwill impairment charge of $ 580.1 million in that quarter within the Europe (majority of the charge), JANZ and Em... | text | 580.1 | monetaryItemType | text: <entity> 580.1 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2023, the OTC Business met the criteria to be classified as held for sale. The Company allocated goodwill to its OTC Business using a relative fair value approach and recorded a goodwill impairment charge of ... | us-gaap:GoodwillImpairmentLoss |
During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within | text | 32.0 | monetaryItemType | text: <entity> 32.0 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within | text | 172.9 | monetaryItemType | text: <entity> 172.9 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
The Company de-designated € 189.2 million of the 2.250 % Euro Senior Notes due 2024 as net investment hedges in the third quarter of 2024 and an additional € 200.0 million in October 2024. The Euro Senior Notes were repaid at maturity during the fourth quarter of 2024. | text | 2.250 | percentItemType | text: <entity> 2.250 </entity> <entity type> percentItemType </entity type> <context> The Company de-designated € 189.2 million of the 2.250 % Euro Senior Notes due 2024 as net investment hedges in the third quarter of 2024 and an additional € 200.0 million in October 2024. The Euro Senior Notes were repaid at maturity... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
for more information), the Company de-designated the € 500 million 2.125 % Euro Senior Notes due 2025 as net investment hedges. The remaining Senior Notes were fully redeemed in October 2024. | text | 2.125 | percentItemType | text: <entity> 2.125 </entity> <entity type> percentItemType </entity type> <context> for more information), the Company de-designated the € 500 million 2.125 % Euro Senior Notes due 2025 as net investment hedges. The remaining Senior Notes were fully redeemed in October 2024. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The principal amount of the foreign currency forward contracts at December 31, 2023 was € 500 million. The contracts matured in July 2024. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> The principal amount of the foreign currency forward contracts at December 31, 2023 was € 500 million. The contracts matured in July 2024. </context> | us-gaap:DerivativeAssetNotionalAmount |
At December 31, 2024, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedges was $ 254.4 million. | text | 254.4 | monetaryItemType | text: <entity> 254.4 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedges was $ 254.4 million. </context> | us-gaap:LongTermDebt |
During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts to... | text | 14.6 | monetaryItemType | text: <entity> 14.6 </entity> <entity type> monetaryItemType </entity type> <context> During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the C... | us-gaap:DerivativeNotionalAmount |
During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts to... | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Co... | us-gaap:DerivativeNotionalAmount |
During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contracts with notional amounts totaling € 600 million. The transactions hedged a portion o... | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contra... | us-gaap:DerivativeNotionalAmount |
During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contracts with notional amounts totaling € 600 million. The transactions hedged a portion o... | text | 600 | monetaryItemType | text: <entity> 600 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contra... | us-gaap:DerivativeNotionalAmount |
At December 31, 2024, the Company expects that approximately $ 19.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. | text | 19.0 | monetaryItemType | text: <entity> 19.0 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the Company expects that approximately $ 19.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. </context> | us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, ... | text | 378.0 | monetaryItemType | text: <entity> 378.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 mi... | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, ... | text | 176.3 | monetaryItemType | text: <entity> 176.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 mi... | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, ... | text | 177.6 | monetaryItemType | text: <entity> 177.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 mi... | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, ... | text | 15.8 | monetaryItemType | text: <entity> 15.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 mil... | us-gaap:BusinessCombinationContingentConsiderationLiability |
Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In additi... | text | 0.775 | percentItemType | text: <entity> 0.775 </entity> <entity type> percentItemType </entity type> <context> Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as ... | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In additi... | text | 484.1 | monetaryItemType | text: <entity> 484.1 </entity> <entity type> monetaryItemType </entity type> <context> Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as... | us-gaap:AccountsReceivableFromSecuritization |
Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In additi... | text | 564.5 | monetaryItemType | text: <entity> 564.5 </entity> <entity type> monetaryItemType </entity type> <context> Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as... | us-gaap:AccountsReceivableFromSecuritization |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 1.650 | percentItemType | text: <entity> 1.650 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respective... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 2.125 | percentItemType | text: <entity> 2.125 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respective... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 422.3 | monetaryItemType | text: <entity> 422.3 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectiv... | us-gaap:EarlyRepaymentOfSeniorDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 432.0 | monetaryItemType | text: <entity> 432.0 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectiv... | us-gaap:LongTermDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 97.8 | percentItemType | text: <entity> 97.8 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectivel... | us-gaap:DebtInstrumentRedemptionPricePercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 206.9 | monetaryItemType | text: <entity> 206.9 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectiv... | us-gaap:EarlyRepaymentOfSeniorDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 208.1 | monetaryItemType | text: <entity> 208.1 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectiv... | us-gaap:LongTermDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 99.4 | percentItemType | text: <entity> 99.4 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectivel... | us-gaap:DebtInstrumentRedemptionPricePercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 3.950 | percentItemType | text: <entity> 3.950 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respective... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 572.5 | monetaryItemType | text: <entity> 572.5 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectiv... | us-gaap:EarlyRepaymentOfSeniorDebt |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.